Compositions of PD-1 antagonists and methods of use
AssigneeAmplimmune, Inc.
InventorsSolomon Langermann, Linda Liu
Life of this patent
Estimating the term…
Abstract
Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.
Claims23
A method of increasing a T cell response in a human subject comprising administering to the subject an anti-B7-H1 antibody or an antigen binding fragment thereof in combination with a potentiating agent selected from the group consisting of cyclophosphamide and an analog of cyclophosphamide,
- wherein the administration of the anti-B7-H1 antibody or antigen binding fragment thereof in combination with the potentiating agent increases a T cell response,
- wherein the dose of the potentiating agent is less than 200 mg/kg,
- wherein the dose of the potentiating agent is not effective to have direct anti-tumor activity,
- and wherein the T cell response achieved by the combination of the anti-B7-H1 antibody and the potentiating agent is greater than the T cell response achieved by administering either the anti-B7-H1 antibody alone or the potentiating agent alone.
A pharmaceutical dosage unit comprising an anti-B7-H1 antibody or an antigen binding fragment thereof and a potentiating agent selected from the group consisting of cyclophosphamide and an analog of cyclophosphamide,
- wherein administration of the dosage unit to a subject increases a T cell response in the subject,
- wherein the dose of the potentiating agent is less than 200 mg/kg,
- wherein the dose of potentiating agent is not effective to have direct anti-tumor activity,
- and wherein the T cell response achieved by the dosage unit is greater than the T cell response achieved by administering either the anti-B7-H1 antibody alone or the potentiating agent alone.
Dependencies are inferred from the claim text.